#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial

Christian Marth; Tjoung-Won Park-Simon; Carol Aghajanian; Alexander Reuss; Shin Nishio; Myong Cheol Lim; Maria Jesús Rubio-Pérez; Mehmet Ali Vardar; Giovanni Scambia; Renaud Sabatier; Charlotte Haslund; Nicoletta Colombo; Anita Chudecka-Glaz; Stephanie Lheureux; Greet Huygh; Fabienne Schochter; Robert M Wenham; Aikou Okamoto; Emily Day; Philipp Harter

doi:10.1136/ijgc-2023-ESGO.899

Citation Tools

Late Breaking Abstracts

06. Ovarian cancer

#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Marth C, Park-Simon T, Aghajanian C, et al

#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial

International Journal of Gynecologic Cancer 2023;33:A428-A429.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password